FGD PET/CT IN SUSPECTED RECURRENT CERVICAL CANCER
Abstract
Carcinoma of uterine cervix represents the fourth most common malignant tumour and the fourth leading cause mortality from cancer in females, and approximately every third woman with cervical carcinoma diagnosis will develop relapse. For follow up and suspicion of recurrence of cervical cancer, various imaging modalities such as CT, MRI and PET/CT can be used. However, role of PET/CT is constantly increasing in these patients and the latest National Comprehensive Cancer Network (NCCN) guideline Version 1.2023 recommends PET/CT as the imaging method of choice for follow-up of patients with disease stage II or higher, and for suspicion of recurrent or metastatic disease. PET/CT shows higher sensitivity and specificity than conventional imaging in suspected recurrent cervical cancer, particularly in evaluation of distant recurrent sites. Additional benefit of PET/CT in these patients is its impact on treatment management in approximately half of the patients. PET/CT also has prognostic role in predicting progression free and overall survival, with patients with positive PET/CT for recurrence showing significantly worse prognosis.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.
2. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36.
3. Miljuš D, Živković Perišić S, Božić Z, editors. Malignant tumours in Republic of Serbia: 2020. Serbian Cancer Registry. Belgrade: Institute of Public Health of Serbia “Dr Milan Jovanović Batut”; 2022.
4. de Foucher T, Bendifallah S, Ouldamer L, Bricou A, Lavoue V, Varinot J, et al. Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group. Eur J Surg Oncol. 2019 Apr;45(4):659-665.
5. Schieda N, Malone SC, Al Dandan O, Ramchandani P, Siegelman ES. Multi-modality organ-based approach to expected imaging findings, complications and recurrent tumour in the genitourinary tract after radiotherapy. Insights Imaging. 2014 Feb;5(1):25-40.
6. Thomas GM, Dembo AJ, Myhr T, Black B, Pringle JF, Rawlings G. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery. Int J Gynecol Cancer. 1993 Jul;3(4):193-198.
7. Gandy N, Arshad MA, Park WE, Rockall AG, Barwick TD. FDG-PET Imaging in Cervical Cancer. Semin Nucl Med. 2019 Nov;49(6):461-470.
8. Petrović J, Macut Đ, Šobić Šaranović D. Radionuclide imaging of neuroendocrine tumors. MedPodml. 2020 Apr 12;71(3):36-42.
9. Palaniswamy SS, Borde CR, Subramanyam P. 18F-FDG PET/CT in the evaluation of cancer cervix: Where do we stand today? Nucl Med Commun. 2018 Jul;39(7):583-592.
10. Meads C, Davenport C, Małysiak S, Kowalska M, Zapalska A, Guest P, et al. Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. BJOG. 2014 Mar;121(4):398-407.
11. Chu Y, Zheng A, Wang F, Lin W, Yang X, Han L, et al. Diagnostic value of 18F-FDG-PET or PET-CT in recurrent cervical cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014 Feb;35(2):144-150.
12. Ding XP, Feng L, Ma L. Diagnosis of recurrent uterine cervical cancer: PET versus PET/CT: a systematic review and meta-analysis. Arch Gynecol Obstet. 2014 Oct;290(4):741-747.
13. Peng NJ, Hu C, Chiu YL, Yu CC, Li CJ, Sheu JJ, et al. Detection of Recurrent Cervical Cancer and Prediction of Its Patient Survival with Serum Squamous-Cell Carcinoma-Antigen and 2-[18F] Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography. Diagnostics (Basel). 2020 Aug 31;10(9):657.
14. Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Sugimura K. Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol. 2008 Oct;18(10):2040-7.
15. Patel-Lippmann K, Robbins JB, Barroilhet L, Anderson B, Sadowski EA, Boyum J. MR Imaging of Cervical Cancer. Magn Reson Imaging Clin N Am. 2017 Aug;25(3):635-649.
16. Bjurberg M, Brun E. Clinical impact of 2-deoxy-2-[18F]fluoro-D-glucose (FDG)-positron emission tomography (PET) on treatment choice in recurrent cancer of the cervix uteri. Int J Gynecol Cancer. 2013 Nov;23(9):1642-1646.
17. Pallardy A, Bodet-Milin C, Oudoux A, Campion L, Bourbouloux E, Sagan C, et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1270-1278.
18. Lai CH, Huang KG, See LC, Yen TC, Tsai CS, Chang TC, et al. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer. 2004 Feb 1;100(3):544-552.
19. Yen TC, Lai CH, Ma SY, Huang KG, Huang HJ, Hong JH, et al. Comparative benefits and limitations of 18F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging. 2006 Dec;33(12):1399-1407.
20. Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol. 2007 Mar;104(3):529-534.
21. Zhou Z, Liu X, Hu K, Zhang F. The clinical value of PET and PET/CT in the diagnosis and management of suspected cervical cancer recurrence. Nucl Med Commun. 2018 Feb;39(2):97-102.
22. Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, et al. Predictive role of post-treatment [18F]FDG PET/CT in patients with uterine cervical cancer. Eur J Radiol. 2012 Aug;81(8):e817-e822.